Format

Send to

Choose Destination
Med Oral Patol Oral Cir Bucal. 2013 May 1;18(3):e433-8.

Use of autologous conditioned serum (Orthokine) for the treatment of the degenerative osteoarthritis of the temporomandibular joint. Review of the literature.

Author information

1
Oral Surgery and Implantology Master Degree Program, University of Barcelona Dental School, Barcelona, Spain.

Abstract

OBJECTIVES:

Treatment of osteoarthritis (OA) using autologous conditioned serum (ACS) has become in recent years an alternative to consider in the approach of the degenerative joint disease of the knee. There is no support in the literature for the use of ACS for the treatment of OA of the temporomandibular joint (TMJ), although the promising results obtained in human patients with knee joint disease and in animal studies are opening the way for its use at the TMJ. The aim of this paper is to conduct a review of the published literature regarding the use of the ACS for the treatment of OA in humans, considering the level of scientific evidence, and following the principles of the evidence-based medicine and dentistry.

MATERIAL AND METHODS:

A PubMed-MEDLINE search was carried out of articles published between 1980 and 2011. After an initial search, a total of 102 articles were obtained, followed by a selection of the most relevant articles according to the topic; a total of 8 articles were selected, which were stratified according to their level of scientific evidence using SORT criteria (Strength of Recommendation Taxonomy).

RESULTS:

At the time of this review, there is no available literature referring the use of ACS at the TMJ. However, the use of the ACS in other joints is well documented, both experimentally and clinically, in humans and animals. The reviewed articles, with a level of evidence 1 and 2 according to the SORT criteria, have generally promising results.

DISCUSSION AND CONCLUSIONS:

The use of ACS in the treatment of OA in joints other than the TMJ, is endorsed by the level of evidence found in the literature, which opens the door to future studies to determine the feasibility of the use of the ACS in the treatment of degenerative OA that affects TMJ.

PMID:
23524415
PMCID:
PMC3668869
DOI:
10.4317/medoral.18373
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Medicina Oral S.L. Icon for PubMed Central
Loading ...
Support Center